Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B.

Yi-Wen HuangChao-Wei HsuSheng-Nan LuMing-Lung YuChien-Wei SuWei-Wen SuRong-Nan ChienChing-Sheng HsuShih-Jer HsuHsueh-Chou LaiAlbert QinKuan-Chiao TsengPei-Jer Chen

Published in: Hepatology international (2020)

In this preliminary study, ropeginterferon alfa-2b, although in only half the number of injections, is as safe and effective as pegylated interferon alfa-2a for chronic hepatitis B.

Keyphrases

hepatitis b virus
replacement therapy
dendritic cells
liver fibrosis
ultrasound guided
immune response
smoking cessation
platelet rich plasma
recombinant human
gestational age